Antibiotic loaded inhalable liposomal nanoparticles against lower respiratory tract infections: Challenges, recent advances, and future perspectives

VK Panthi, KE Fairfull-Smith, N Islam - Journal of Drug Delivery Science …, 2024 - Elsevier
Lower respiratory tract infections (LRTIs) are inherited disorders which often causes chronic
respiratory infections for which patients repeatedly receive oral antibiotics, particularly …

[图书][B] Nelson's pediatric antimicrobial therapy

JS Bradley - 2012 - publications.aap.org
Welcome to the 29th edition of Nelson's Pediatric Antimicrobial Therapy, the third edition
written during the COVID-19 pandemic, which continues to significantly affect our lives and …

Inhaled antibiotics: A promising drug delivery strategies for efficient treatment of lower respiratory tract infections (LRTIs) associated with antibiotic resistant biofilm …

N Islam, D Reid - Respiratory Medicine, 2024 - Elsevier
Antibiotic-resistant bacteria associated with LRTIs are frequently associated with inefficient
treatment outcomes. Antibiotic-resistant Streptococcus pneumoniae, Haemophilus …

Inhalation of vaccines and antiviral drugs to fight respiratory virus infections: reasons to prioritize the pulmonary route of administration

R Heida, HW Frijlink, WLJ Hinrichs - Mbio, 2023 - Am Soc Microbiol
Many of the current pandemic threats are caused by viruses that infect the respiratory tract.
Remarkably though, the majority of vaccines and antiviral drugs are administered via …

Structure–Interaction Relationship of Polymyxins with Lung Surfactant

X Jiang, NA Patil, Y Xu… - Journal of Medicinal …, 2023 - ACS Publications
Multidrug-resistant Gram-negative bacteria present an urgent and formidable threat to the
global public health. Polymyxins have emerged as a last-resort therapy against these …

[HTML][HTML] Traits, trends and hits of orphan drug designations in cystic fibrosis

E Costa, S Girotti, HA van den Ham, M Cipolli… - Journal of Cystic …, 2023 - Elsevier
Abstract Background In the United States (US) and in Europe, cystic fibrosis (CF) qualifies as
a rare disease, thus positioning the field to benefit from regulatory incentives provided by …

[HTML][HTML] Optimizing in vitro phage-ciprofloxacin combination formulation for respiratory therapy of multi-drug resistant Pseudomonas aeruginosa infections

Q Hong, RYK Chang, O Assafiri, S Morales… - International Journal of …, 2024 - Elsevier
Respiratory infection caused by multi-drug resistant (MDR) Pseudomonas aeruginosa is
challenging to treat. In this study, we investigate the optimal dose of anti-pseudomonas …

Considerations for the use of inhaled antibiotics for Pseudomonas aeruginosa in people with cystic fibrosis receiving CFTR modulator therapy

PR Burgel, M Ballmann, P Drevinek… - BMJ open …, 2024 - bmjopenrespres.bmj.com
The major cause of mortality in people with cystic fibrosis (pwCF) is progressive lung
disease characterised by acute and chronic infections, the accumulation of mucus, airway …

Structural Insights into the Lipopolysaccharide Transport (Lpt) System as a Novel Antibiotic Target

Y Yoon, S Song - Journal of Microbiology, 2024 - Springer
Lipopolysaccharide (LPS) is a critical component of the extracellular leaflet within the
bacterial outer membrane, forming an effective physical barrier against environmental …

Development of Quinazolinone Derivatives as Modulators of Virulence Factors of Pseudomonas aeruginosa Cystic Fibrosis Strains

G Carullo, G Di Bonaventura, S Rossi, V Lupetti… - Molecules, 2023 - mdpi.com
Pseudomonas aeruginosa (PA), one of the ESKAPE pathogens, is an opportunistic Gram-
negative bacterium responsible for nosocomial infections in humans but also for infections in …